Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Bayer AG
Bear Case (25th pct.)
115.9% vs price
Base Case (Median)
174.3% vs price
Bull Case (75th pct.)
232.8% vs price
◇ = Current price | | Bear | Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $55.76 | 291.3% | High (40%) |
| EV/EBITDA | $22.42 | 57.3% | Medium (20%) |
Based on 2 out of 7 methods, BAYRY appears undervalued at the current price of $14.25. The base case fair value of $39.09 implies 174.3% upside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.